Your browser doesn't support javascript.
loading
Effect of bortezomib combined with doxorubicin on lymphoblastic lymphoma Molt-4 cells / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma ; (12): 132-135, 2013.
Article Dans Chinois | WPRIM | ID: wpr-475327
ABSTRACT
Objective To investigate the effect of bortezomib combined with doxorubicin on lymphoblastic lymphoma cell line Molt-4.Methods Molt-4 cells were cultured in the presence of bortezomib and doxorubicin,cell viability was monitored by CCK-8 and trypan-blue exclusion.Apoptosis was detected by flow cytometry and mitochondrial membrane potential,expression of Fas was also measured with flow cytometry.Results Molt-4 cell proliferation was substantially inhibited in concentration-dependent manners when treated with either bortezomib or doxorubicin.The combination of both drugs synergistically inhibited Molt-4 cell proliferation at 48 hours [(57.24±0.10) %].Combination therapy further enhanced bortezomib and doxorubicin induced apoptosis [48 h (23.08±1.25) %] (P < 0.05).Detection of mitochondrial membrane potential showed that combination therapy could promote apoptosis (15.84 %,5.38 %,5.52 %) but did not significantly change the level of Fas expression (P > 0.05).Conclusion Combination therapy of bortezomib with doxorubicin efficiently inhibits proliferation and induces apoptosis of Molt-4 cells.Activation of mitochondrial and intrinsic apoptotic pathway may play important roles.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Journal of Leukemia & Lymphoma Année: 2013 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Journal of Leukemia & Lymphoma Année: 2013 Type: Article